We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Power3 Medical's CSO to Address OncoProteomics World Congress;
News

Power3 Medical's CSO to Address OncoProteomics World Congress;

Power3 Medical's CSO to Address OncoProteomics World Congress;
News

Power3 Medical's CSO to Address OncoProteomics World Congress;

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Power3 Medical's CSO to Address OncoProteomics World Congress; "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Power3 Medical Products, Inc. has announced that its CSO, Ira L. Goldknopf, PhD. has been invited to present at the OncoProteomics World Congress in San Francisco on April 27-28, 2006.

The presentation will be entitled "Convergence of ProteomeDiagnsotics and PharmacoProteomics towards Personalized Medicine - Examples from Breast Cancer and Leukemia." Dr. Goldknopf's talk will cover the Company's dual breast cancer diagnostic platforms: 1) NAFTest™ and biomarkers and 2) blood serum test and biomarkers, as well as the Company's 3) bone marrow test, biomarkers, and therapeutic target for drug resistant and sensitive leukemia.

"We are particularly gratified that Dr. Kewal Jain, an internationally prominent thought leader on proteomics science, technologies and markets, has seen fit to feature Power3 Medical's work at such an important World Congress. We are delighted that the biotechnology community is taking notice of our efforts and accomplishments in breast cancer and drug resistant leukemia," said Dr. Goldknopf. "This invitation is a significant validation of Power3 Medical's position as a leader in advancing the science of proteomics for development of targeted diagnostics and therapeutics for cancer."

The Company is conducting ongoing clinical validation trials for their breast cancer tests and biomarkers at 3 sites, Mercy Woman's Center, a high risk breast cancer clinic in Oklahoma City, with Dr. Alan Hollingsworth, The New York University Medical Center, in New York City with Dr. David Fishman, and The Obstetric and Gynecological Associates at the Woman's Hospital in Houston with Dr. Leroy Leeds.

Advertisement